<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Antihypertensive therapy and progression of chronic kidney disease: Experimental studies
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Antihypertensive therapy and progression of chronic kidney disease: Experimental studies
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Antihypertensive therapy and progression of chronic kidney disease: Experimental studies
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            George L Bakris, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gary C Curhan, MD, ScD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William J Elliott, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John P Forman, MD, MSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 30, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Extensive studies in animals and humans have shown that progression of a variety of chronic kidney diseases may be largely due to secondary hemodynamic and metabolic factors, rather than the activity of the underlying disorder. Identification of these factors, such as intraglomerular hypertension and glomerular hypertrophy, is important clinically because they can be treated, possibly preventing or minimizing further glomerular injury [
         <a href="#rid1">
          1-3
         </a>
         ]. A review of the mechanisms by which these alterations might occur and how they might induce glomerular injury is available elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7181.html" rel="external">
          "Secondary factors and progression of chronic kidney disease"
         </a>
         .)
        </p>
        <p>
         An important component of this approach is antihypertensive therapy with blockers of the renin angiotensin system (RAS), specifically use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). The experimental studies supporting this approach will be reviewed here. The clinical trials and recommendations are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">
          "Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PREFERENTIAL EFFECT OF RAS BLOCKERS ON RENAL HEMODYNAMICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         From a therapeutic viewpoint, lowering systemic blood pressure is beneficial in a variety of experimental kidney diseases, at least in part by reducing intraglomerular pressure [
         <a href="#rid1">
          1,2,4-6
         </a>
         ]. Renin angiotensin system (RAS) blockers, including angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), appear to be particularly effective in this regard; this effect may be related to reversal of the angiotensin II-induced increase in resistance at the efferent or postglomerular arteriole [
         <a href="#rid4">
          4,5
         </a>
         ]. Dilation of the efferent arteriole will facilitate blood movement out of the glomerulus, lowering the intraglomerular pressure independent of any change in systemic blood pressure. A brief review of the actions of angiotensin II on glomerular hemodynamics is available elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3873.html" rel="external">
          "Renal effects of ACE inhibitors in hypertension"
         </a>
         .)
        </p>
        <p>
         It is presumed that the deleterious effect of angiotensin II represents
         <strong>
          local generation
         </strong>
         since circulating levels are normal or reduced (due to volume expansion) in many patients with chronic kidney disease [
         <a href="#rid7">
          7
         </a>
         ]. In the remnant kidney model of chronic kidney failure, for example, endothelial injury or activation is associated with enhanced expression of angiotensinogen mRNA, which may then lead to increases in angiotensinogen and angiotensin II production [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Angiotensin receptor blockers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data in animal models have found that ARBs are as effective as ACE inhibitors [
         <a href="#rid9">
          9-13
         </a>
         ], albeit with a lesser antiproteinuric effect [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p>
         With experimental models, some variability in results may be due to differences in dosing, which was mostly based on the maximal blood pressure reductions. In some experimental studies, much higher levels of the angiotensin-I receptor are noted in kidney parenchyma than in vascular smooth muscle cells [
         <a href="#rid16">
          16
         </a>
         ]. This suggests that higher doses of ARBs may be required to effectively block kidney parenchymal receptors than the doses used to lower blood pressure. These much higher doses may confer effects beyond that obtained with blood pressure lowering, particularly decreased inflammation and superior nephroprotection.
        </p>
        <p>
         This hypothesis was evaluated in the 5/6 renal ablation model in which conventional doses of
         <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">
          losartan
         </a>
         (L50), supplemented with
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         and
         <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">
          hydralazine
         </a>
         to achieve similar blood pressures, were compared with 10-fold higher doses of losartan (L500) [
         <a href="#rid17">
          17
         </a>
         ]. Among the effects measured, glomerular pressure and glomerular filtration rate were similar with both L50 and L500, although blood pressure and renal vascular resistance were lower with L500. Although kidney injury and albuminuria were partially reduced by L50 at four months postsurgery, L500 completely arrested kidney inflammation and injury and was associated with regression of albuminuria. This finding suggests that full blockade of angiotensin-I receptors requiring much higher doses of ARBs may be associated with maximum nephroprotection.
        </p>
        <p>
         Human studies show that ACE inhibitors and ARBs have similar benefits on albuminuria and progression of kidney function loss in both diabetic and nondiabetic kidney disease [
         <a href="#rid18">
          18-20
         </a>
         ]. Any noncomparable effects of ACE inhibitors and ARBs may have resulted from variable blood pressure-lowering efficacy of different ARBs [
         <a href="#rid18">
          18,21-23
         </a>
         ]. In addition, real-world evidence from a large observational study (including approximately two million people) found that there was no difference in efficacy of blood pressure control between ACE inhibitors and ARBs, but ARBs were better tolerated [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">
          "Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Other antihypertensive drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other drugs, such as
         <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">
          hydralazine
         </a>
         , dihydropyridine calcium channel blockers, diuretics, and beta blockers, have not been shown to reverse intraglomerular hypertension (because they do not produce preferential efferent dilatation) and therefore may be less likely to protect against progressive glomerular injury  (
         <a class="graphic graphic_figure graphicRef53771" href="/z/d/graphic/53771.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid5">
          5,25
         </a>
         ]. Hydralazine and the dihydropyridine calcium channel blockers (eg,
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">
          amlodipine
         </a>
         ), appear to produce prominent afferent or preglomerular arteriolar dilatation [
         <a href="#rid5">
          5,6,26,27
         </a>
         ]. Decreased resistance at this site will allow more of the systemic pressure to be transmitted to the glomerulus, possibly producing no change or even an elevation in intraglomerular pressure, despite the associated reduction in systemic blood pressure. Increased efferent resistance also may occur, as the drug-induced vasodilatation leads to activation of the renin-angiotensin system. In comparison to nifedipine and amlodipine, nondihydropyridine calcium channel blockers (
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         and
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         ) are less potent vasodilators and have been shown to decrease the resistance at the efferent arteriole [
         <a href="#rid6">
          6,25,28
         </a>
         ].
        </p>
        <p>
         Studies using calcium channel blockers in experimental models of kidney disease have revealed conflicting results [
         <a href="#rid6">
          6,26
         </a>
         ]: some have shown increasing proteinuria (consistent with a rise in intraglomerular pressure) and little protection against glomerulosclerosis [
         <a href="#rid27">
          27
         </a>
         ], while others have shown benefit by mechanisms that may in part be independent of the intraglomerular pressure. (See
         <a class="medical medical_review" href="/z/d/html/7181.html" rel="external">
          "Secondary factors and progression of chronic kidney disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          OTHER ACTIONS OF ACE INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to lowering the intraglomerular pressure, experimental studies suggest that the beneficial effect of renin angiotensin system (RAS) blockers may be related to a number of other factors  (
         <a class="graphic graphic_figure graphicRef86383" href="/z/d/graphic/86383.html" rel="external">
          figure 2
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Angiotensin II is a growth factor; therefore, diminishing its production may minimize glomerular hypertrophy which, by decreasing the capillary radius, can reduce the tension on the glomerular capillary wall [
         <a href="#rid29">
          29,30
         </a>
         ]. This protective effect also may occur in extrarenal vessels, as the degree of vascular hypertrophy in hypertensive animals with kidney disease is less following therapy with an angiotensin-converting enzyme (ACE) inhibitor than with the triad of a thiazide diuretic, reserpine, and
         <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">
          hydralazine
         </a>
         [
         <a href="#rid10">
          10
         </a>
         ]. Inhibition of local angiotensin II generation may be responsible for this vasculoprotective effect. (See
         <a class="medical medical_review" href="/z/d/html/3815.html" rel="external">
          "Renin-angiotensin system inhibition in the treatment of hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Angiotensin II, either directly or via increased glomerular pressure, can enhance the release of extracellular matrix and collagen from mesangial and tubular cells, thereby promoting both glomerular and tubulointerstitial fibrosis [
         <a href="#rid8">
          8,29-32
         </a>
         ]. This effect is mediated at least in part by enhanced release of transforming growth factor-beta, matrix proteins, platelet-derived growth factor, and plasminogen activator inhibitor-I [
         <a href="#rid8">
          8,31,33-36
         </a>
         ]. Administration of an ACE inhibitor and/or angiotensin receptor blocker (ARB) decreases cytokine release, due most likely to a fall in glomerular pressure and/or reversal of the direct action of angiotensin II [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The ability of ACE inhibitors or ARBs to partially block the profibrotic effect of angiotensin II may be particularly due to their effect to decrease transforming growth factor-beta and plasminogen activator inhibitor-I levels (among others), and/or increase hepatocyte growth factor concentrations [
         <a href="#rid37">
          37
         </a>
         ]. Due to these effects, ACE inhibitors and ARBs may help to reverse kidney sclerosis, as observed in multiple animal models of progressive kidney dysfunction [
         <a href="#rid35">
          35,36,38
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An ACE inhibitor may directly improve the size selective properties of the glomerulus, thereby preventing the accumulation of macromolecules in the mesangium and a secondary increase in mesangial matrix production [
         <a href="#rid39">
          39
         </a>
         ].
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          Diltiazem
         </a>
         may have similar effects, while
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         worsens size selective properties [
         <a href="#rid40">
          40
         </a>
         ]. Whether improvement in size-selective properties is related to or is independent of the associated reduction in intraglomerular pressure is not clear.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inhibition of angiotensin II production via ACE inhibition also lowers the release of aldosterone. (See
         <a class="medical medical_review" href="/z/d/html/7181.html" rel="external">
          "Secondary factors and progression of chronic kidney disease", section on 'Aldosterone'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Due to decreased degradation, ACE inhibitors increase bradykinin concentrations, which may ameliorate kidney tubulointerstitial fibrosis. Support for this was provided by an animal model in which unilateral ureteral obstruction-induced interstitial fibrosis was significantly increased in bradykinin B2 receptor knockout mice [
         <a href="#rid41">
          41
         </a>
         ]. Bradykinin may dampen fibrosis by increasing extracellular matrix degradation via enhanced metalloproteinase-2 and other enzymatic activity. A similar benefit by this mechanism would not be expected with an ARB, which does not increase bradykinin levels.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          POSSIBLE ROLE OF ENDOTHELIN
         </span>
         <span class="headingEndMark">
          —
         </span>
         Endothelin, a potent peripheral vasoconstrictor, has also been implicated in the progression of kidney failure, due in part to its ability to stimulate glomerular hypertrophy and extracellular matrix stimulation [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2199613">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Renal hemodynamics and progressive kidney injury
         </strong>
         – Progression of a variety of chronic kidney diseases may be largely due to secondary hemodynamic and metabolic factors, rather than the activity of the underlying disorder. Antihypertensive therapy, particularly with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), is one important component of reducing risk of secondary kidney injury. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Renin angiotensin system (RAS) blockers
         </strong>
         – Data in animal models concerning the efficacy of ARBs in protecting against progressive kidney disease are conflicting. Some studies have found that ARBs are as effective as ACE inhibitors, whereas other studies show they are inferior. However, while there may be differences in animal models, human studies show no difference in albuminuria reduction at similar blood pressure levels and no difference in slowing progression of kidney disease. (See
         <a class="local">
          'Angiotensin receptor blockers'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to lowering the intraglomerular pressure, experimental studies suggest that the beneficial effect of RAS blockers may also be related to inhibition of other effects of angiotensin II, including glomerular hypertrophy and fibrosis. (See
         <a class="local">
          'Other actions of ACE inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other antihypertensive agents
         </strong>
         –
         <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">
          Hydralazine
         </a>
         and dihydropyridine calcium channel blockers (eg,
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">
          amlodipine
         </a>
         ) appear to produce prominent afferent or preglomerular arteriolar dilatation, and result in an elevation in intraglomerular pressure secondary to inhibiting renal autoregulation despite the associated reduction in systemic blood pressure. By comparison, nondihydropyridine calcium channel blockers (
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         or
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         ) are less potent afferent vasodilators and partially decrease efferent arteriole tone and only partially affect autoregulation. (See
         <a class="local">
          'Other antihypertensive drugs'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Jacobson HR. Chronic renal failure: pathophysiology. Lancet 1991; 338:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hollenberg NK, Raij L. Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy. Arch Intern Med 1993; 153:2426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu HT. Progression of chronic renal failure. Arch Intern Med 2003; 163:1417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunner HR. ACE inhibitors in renal disease. Kidney Int 1992; 42:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson S, Rennke HG, Garcia DL, Brenner BM. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989; 36:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown SA, Walton CL, Crawford P, Bakris GL. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993; 43:1210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenberg ME, Smith LJ, Correa-Rotter R, Hostetter TH. The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int 1994; 45:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee LK, Meyer TW, Pollock AS, Lovett DH. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest 1995; 96:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kakinuma Y, Kawamura T, Bills T, et al. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 1992; 42:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zoja C, Donadelli R, Corna D, et al. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist. Am J Kidney Dis 1997; 29:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ots M, Mackenzie HS, Troy JL, et al. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 1998; 9:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zoja C, Corna D, Camozzi D, et al. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002; 13:2898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ichikawa I. Will angiotensin II receptor antagonists be renoprotective in humans? Kidney Int 1996; 50:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutchison FN, Cui X, Webster SK. The antiproteinuric action of angiotensin-converting enzyme is dependent on kinin. J Am Soc Nephrol 1995; 6:1216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonçalves AR, Fujihara CK, Mattar AL, et al. Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory. Am J Physiol Renal Physiol 2004; 286:F945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujihara CK, Velho M, Malheiros DM, Zatz R. An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int 2005; 67:1913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351:1952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakris GL, Zhao L, Kupfer S, et al. Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. J Clin Hypertens (Greenwich) 2018; 20:694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bönner G, Bakris GL, Sica D, et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens 2013; 27:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White WB, Cuadra RH, Lloyd E, et al. Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. J Hypertens 2016; 34:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen R, Suchard MA, Krumholz HM, et al. Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study. Hypertension 2021; 78:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kvam FI, Ofstad J, Iversen BM. Effects of antihypertensive drugs on autoregulation of RBF and glomerular capillary pressure in SHR. Am J Physiol 1998; 275:F576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakris GL. The effects of calcium antagonists on renal hemodynamics, urinary protein excretion, and glomerular morphology in diabetic states. J Am Soc Nephrol 1991; 2:S21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffin KA, Picken MM, Bidani AK. Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995; 96:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65:1991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolf G, Neilson EG. Angiotensin II as a renal growth factor. J Am Soc Nephrol 1993; 3:1531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fogo AB. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 2000; 35:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93:2431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boffa JJ, Lu Y, Placier S, et al. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003; 14:1132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shankland SJ, Ly H, Thai K, Scholey JW. Increased glomerular capillary pressure alters glomerular cytokine expression. Circ Res 1994; 75:844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998; 31:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Remuzzi A, Gagliardini E, Donadoni C, et al. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 2002; 62:885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adamczak M, Gross ML, Krtil J, et al. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 2003; 14:2833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma L, Fogo AB. Role of angiotensin II in glomerular injury. Semin Nephrol 2001; 21:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma LJ, Nakamura S, Whitsitt JS, et al. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 2000; 58:2425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Remuzzi A, Puntorieri S, Battaglia C, et al. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 1990; 85:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998; 54:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schanstra JP, Neau E, Drogoz P, et al. In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 2002; 110:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barton M, Sorokin A. Endothelin and the glomerulus in chronic kidney disease. Semin Nephrol 2015; 35:156.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7171 Version 18.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1678092" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Chronic renal failure: pathophysiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8215747" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12824091" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Progression of chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1405331" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : ACE inhibitors in renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2681929" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Short and long term effects of antihypertensive therapy in the diabetic rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8391095" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8164426" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The paradox of the renin-angiotensin system in chronic renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7635988" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1522231" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1635354" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9016898" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9527398" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12444208" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8840302" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Will angiotensin II receptor antagonists be renoprotective in humans?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8589289" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The antiproteinuric action of angiotensin-converting enzyme is dependent on kinin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15075190" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15840039" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : An extremely high dose of losartan affords superior renoprotection in the remnant model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15516696" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11565518" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11565517" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29504252" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23514842" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26766564" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34304580" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9755129" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Effects of antihypertensive drugs on autoregulation of RBF and glomerular capillary pressure in SHR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1932640" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The effects of calcium antagonists on renal hemodynamics, urinary protein excretion, and glomerular morphology in diabetic states.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7635974" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15149313" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Differential effects of calcium antagonist subclasses on markers of nephropathy progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8507808" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Angiotensin II as a renal growth factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10676714" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8200978" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12707384" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7923630" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Increased glomerular capillary pressure alters glomerular cytokine expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9453300" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12164870" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Effect of angiotensin II antagonism on the regression of kidney disease in the rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14569093" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11709802" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Role of angiotensin II in glomerular injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11115076" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1688888" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9734613" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12163456" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : In vivo bradykinin B2 receptor activation reduces renal fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25966347" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Endothelin and the glomerulus in chronic kidney disease.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
